Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 70.98 USD 0.75% Market Closed
Market Cap: 3.6B USD
Have any thoughts about
Axonics Inc?
Write Note

Axonics Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Axonics Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Axonics Inc
NASDAQ:AXNX
Total Liabilities & Equity
$774.2m
CAGR 3-Years
11%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Total Liabilities & Equity
$57.3B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
16%
Boston Scientific Corp
NYSE:BSX
Total Liabilities & Equity
$38.1B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
9%
Stryker Corp
NYSE:SYK
Total Liabilities & Equity
$43.8B
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
10%
Abbott Laboratories
NYSE:ABT
Total Liabilities & Equity
$74.4B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Liabilities & Equity
$17.7B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
17%
No Stocks Found

Axonics Inc
Glance View

Market Cap
3.6B USD
Industry
Health Care
Economic Moat
Narrow

Axonics Inc., a prominent player in the medical technology landscape, has carved a niche for itself by focusing diligently on the development and commercialization of innovative solutions for bladder and bowel dysfunction. Founded in 2012, the company's primary product is its Sacral Neuromodulation (SNM) system, designed to treat urinary and fecal incontinence. What differentiates Axonics is its dedication to addressing a pervasive issue with an underpinning focus on patient-centric design and effective long-term treatment. Its SNM system offers users rechargeable batteries, providing a less invasive and more cost-effective solution compared to traditional systems. This technology not only addresses significant medical needs but also aligns well with a growing trend toward minimally invasive solutions in medtech. The operational model of Axonics is straightforward yet well-suited to drive profitability. Revenues primarily derive from the sales of its SNM system, which is marketed directly to healthcare providers and practitioners. This involves an intricate network of sales representatives and a hands-on approach to training medical professionals on the benefits and use of their systems, ensuring that the technology translates efficiently into patient treatment. By focusing extensively on a specific segment within the broader medical device industry, Axonics has positioned itself to capitalize on a substantial market opportunity, driven by an aging population and increasing rates of incontinence-related conditions. This strategic approach not only underscores its commitment to delivering effective healthcare solutions but also signifies its potential for sustained growth within a competitive landscape.

AXNX Intrinsic Value
33.82 USD
Overvaluation 52%
Intrinsic Value
Price

See Also

What is Axonics Inc's Total Liabilities & Equity?
Total Liabilities & Equity
774.2m USD

Based on the financial report for Sep 30, 2024, Axonics Inc's Total Liabilities & Equity amounts to 774.2m USD.

What is Axonics Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
44%

Over the last year, the Total Liabilities & Equity growth was 17%. The average annual Total Liabilities & Equity growth rates for Axonics Inc have been 11% over the past three years , 44% over the past five years .

Back to Top